PAYSON, Ariz. –
Ally Biotech, a science-based company and provider of leading-edge bioactive delivery solutions for cannabinoids, today announces the appointment of Charles C. Johnson, Ph.D., to the role of Chief Science Officer.
With a Ph.D. in Analytical Chemistry from Virginia Tech, Dr. Charles “Chuck” Johnson comes to Ally Biotech with decades of experience in FDA regulatory compliance, LEAN (TPS) principles in product development and manufacturing, competitive market analysis, mergers and acquisitions, and technical sales. Most recently, he has provided consultation services and served as the Chief Science and Operations Officer in the hemp and cannabis sectors, including industrial farming, extraction, refining, GMP production, nutraceuticals, and FDA compliance.
“With Dr. Johnson’s expertise in both mainstream product development, manufacturing expertise, and his consultation experience and passion for the hemp and cannabis sectors, he is an ideal addition to our team at Ally Biotech,” said Jim Mackowiak, company president.
Like many in the sector, Dr. Johnson’s interest and entry into the cannabis industry is personal. His expertise in the hemp and cannabis sectors are inspired by his own father’s health experiences who, suffering from rheumatoid arthritis, experienced multiple side effects and setbacks from conventional medicine.
“After seeing what my father went through, I resolved myself to find a better way,” Dr. Johnson said. “This emerging industry has provided me the opportunity to thrive in the pursuit of that better way. I look forward to leading Ally Biotech’s science team as we continue to pursue technology innovation in the THC industry.”
Ally Biotech is a cannabis science company behind the Lipofusion delivery technology, considered the next generation of oral delivery technologies for the cannabinoid market. Their proprietary nanoliposomal technology protects bioactives from degradation in the digestive system and provides effective and increased absorption on the cellular level. They recently acquired the Arizona-based Chill Pill brand, an expansive line of easy-to-swallow THC soft gels.
For more information on Ally Biotech, visit www.AllyBiotech.com.
About Ally Biotech:
Headquartered in Payson, Arizona, Ally Biotech offers highly bioavailable products to leading manufacturers and dispensaries of cannabis products since 2018. The company recently acquired the Chill Pill line of products. The company’s Lipofusion delivery technology combines nanotechnology and liposomal science to speed product differentiation and innovation. Ally Biotech offers product development services, and manufacturing-ready, water soluble Lipofusion THC that can be utilized as a raw ingredient in powder or liquid form in a variety of products. All of the company’s products undergo rigorous testing for purity, potency, safety and efficacy at third-party laboratories. For more information, visit AllyBiotech.com. For more information about the Chill Pill, visit ChillPillsAZ.com.
